Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

India 2019 – R&D Highs, Compliance Woes And Other Lows

Dec 23 2019

• By Anju Ghangurde and Vibha Ravi

Scrip Perspectives 2019 to 2020 — 2019 Saw Peaks And Troughs For India Pharma Inc

Related Content

A Warning Letter Trend Surprise: Good In India, Bad In South Korea

Oct 04 2019

Graft Trail: Top Level Indian Regulatory Official Arrested

Aug 20 2019

Indian Firms May Want To Slow March Into China

Nov 20 2019

US Trastuzumab Competition Heats Up

Dec 02 2019

FDA Warning Letter Blasts Glenmark

Oct 21 2019

Torrent Gets FDA Warning Letter

Oct 17 2019

The Factory Floor: Suanfarma Expands API Capacity With Sandoz Deal In Italy

Oct 14 2019

Mylan-Biocon’s Ogivri First Off Block In Australia But Competition In Sight

Aug 06 2019

Manufacturing Round-Up: Dr Reddy’s Receives Another Form 483

Sep 30 2019

Lupin Slapped With Fresh FDA Warning Letter

Sep 24 2019

FDA Holds Zydus Cadila Responsible For ‘Repeat Violations’

Nov 19 2019

The Factory Floor: Aurobindo Receives Another Form 483

Nov 15 2019

Lupin Ends 2018 On High, Strikes Large MALT1 Deal With AbbVie

Dec 24 2018

Equillium Will Study In-Licensed Itolizumab In Three Indications In 2019

Jul 09 2019

China Ho! Sun Strikes Deals For Ilumya, Cequa

Jun 28 2019

Lupin Q2 Hit By US Settlement, Japan Injectables Selloff

Nov 11 2019

Sun Upbeat On IL-23 Prospects In US, Ilumya Faring ‘Reasonably’

Nov 11 2019

Monroe Site Commercialization ‘Critical’ For Glenmark’s US Step-Up

Nov 18 2019

Levorphanol Write-Down Dents Zydus in Q2 But Saroglitazar Expectations Build

Nov 15 2019

Lupin’s Karkaria On Biosimilars Pushback And Interchangeability

Nov 26 2019

Sun Allies With AZ To Drive China Oncology Push

Nov 07 2019

Dr Reddy’s De Vré On Momentum In US Biosimilars Market, Interchangeability

Oct 04 2019

Ranbaxy Brothers Arrested, Downward Spiral Intensifies

Oct 11 2019

Early Indian Promise For A Cut-Price CAR-T Therapy

Oct 08 2019

Boehringer Ingelheim Snaps Up Lupin's MEK Inhibitor For Difficult-To-Treat Cancers

Sep 04 2019

Zydus Cadila Strides Ahead With NASH Filing In India

Dec 06 2019

India’s Top Court Tells Singhs To Come Up With Plan To Pay Daiichi, Uphold Nation’s ‘Honor’

Mar 18 2019

Aurobindo Faulted In US FDA Warning Letter For Poor Root Cause Investigations

Jul 03 2019

FDA’s Record-Number GMP Warnings In FY 2019 Included First Of A Kind

Dec 17 2019

Related Companies

Aurobindo Pharma Limited

Glenmark Pharmaceuticals Limited

Torrent Pharmaceuticals Ltd.

Cadila Pharmaceuticals Ltd.

Sun Pharmaceutical Industries Ltd.

Dr. Reddy's Laboratories Ltd.

Lupin Limited

Boehringer Ingelheim GmbH

AbbVie Inc.

Zydus Lifesciences Limited

Merck & Co., Inc.

AstraZeneca PLC

China Medical System Holdings Limited

Cipla Limited

Alembic Pharmaceuticals Limited

Biocon, Ltd.

Viatris Inc.

Roche Holding AG

Genentech, Inc.

Amgen, Inc.

Allergan plc

Additional Topics

India Asia Pacific Commercial Strategy Manufacturing Biosimilars BioPharmaceutical

More from India

More from Focus On Asia

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window